Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Emperra Launches First Bluetooth-Enabled Insulin Pen For Diabetes Management



The ESYSTA BT pen using Bluetooth, is designed to be used in combination with a wireless blood glucose meter as a complete diabetes management system. Image courtesy of Emperra.

Tweetables from this article:

Tweet: World’s first #Bluetooth-enabled insulin pen capable of wirelessly transmitting information #Diabetes http://ctt.ec/5c0yt+World’s first Bluetooth-enabled insulin pen capable of wirelessly transmitting information.

Tweet: In study conducted by Emperra the ESYSTA system was found to reduce HbA1c by 1% over a 12 month period #Diabetes http://ctt.ec/qkXxG+In study conducted by Emperra the ESYSTA system was found to reduce HbA1c by 1% over a 12 month period.

Share this!

August 11, 2016 | by Sarah Massey, M.Sc.

Germany’s Emperra GmbH is preparing to launch the world’s first insulin pen, capable of wirelessly transmitting information on insulin injections to an external blood glucose management device. The ESYSTA BT pen using Bluetooth, is designed to be used in combination with a wireless blood glucose meter as a complete diabetes management system.

Both the ESYSTA portal and the ESYSTA app have received a CE mark for compliance certification. Emperra plans to use currently-available scientific data from diabetic patients in Germany to secure US Food and Drug Administration (FDA) approval later this year.

“The smart insulin pen and corresponding software appeal to patients and doctors who prefer state-of-the-art technical solutions and who have recognized that the digitalization of diabetes management is a simple and reliable solution,” said Dr. Christian Krey, CEO of Emperra GmbH. With a high level of data quality and security, the ESYSTA BT pen could help doctors telemedically adjust insulin levels for patients with both type 1 and type 2 diabetes.

The mobile ESYSTA app allows patients to keep a digital blood glucose diary, as well as relay treatment recommendations to the patient. The smart insulin pen is also subject to reimbursement as a medical device, by all statutory health insurers in Germany.

“We are proud that we can use all U-100 insulins in 3 ml cartridges with the development of specially customized adapters,” said Dr. Janko Schildt, Founder and Managing Director responsible for medicine and technology. “As a result, every insulin-dependent patient can be equipped with ESYSTA®, regardless of whether the insulin comes from Lilly, Sanofi or Novo Nordisk.

“Even the accidental mixing up of basal and bolus ESYSTA® pens and priming (deaeration) can be identified on the ESYSTA® portal,” Schildt continued. “In combination with real insulin application data, I believe as a doctor that this constitutes an evolutionary leap for the digital age of diabetes management.”

Diabetic patients often measure their blood glucose levels and inject insulin several times throughout the day, making accurate documentation of these events essential. By automating documentation and analysis, patients and physicians can work together towards better diabetes management.

“Often the patient’s entries are difficult to read or simply forgotten, analyzing the data is laborious and time-consuming,” said Dr. Klaus Kusterer, a diabetologist from Mannheim, Germany. “Digital data recording can make a huge contribution to improving diabetes management. The data is complete and unadulterated and the patient no longer has to remember to document their data at all.”

In a study conducted by Emperra, in collaboration with a health insurance company, the ESYSTA system was found to help patients reduce their glycated hemoglobin (HbA1c) – a measure used to assess the average blood glucose level over a period of time – by one percent, over a twelve month period. This finding was also associated with a decreased use of injectable insulin – a major cost factor for patients and payers.

Keywords: Diabetes, Insulin, Medical Device


Share this with your colleagues!

Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News

FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News

One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


Top 5 Most Impactful Tweets in Life Sciences During the Last Week


EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider

Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology

Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn

eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.